Biogen has reported positive interim results from the ongoing, pivotal Phase III EVOLVE-MS-1 clinical trial of diroximel fumarate in patients with relapsing multiple sclerosis (MS).

According to the data, the drug was generally well-tolerated and significantly reduced disease activity.

Diroximel fumarate is an oral candidate being developed in alliance with Alkermes.

The single-arm, open-label, two-year EVOLVE-MS-1 trial is designed to assess the safety and efficacy of the therapeutic in around 1,000 patients with relapsing-remitting MS.

Interim data were obtained from 696 subjects treated with diroximel fumarate for a median of around one year. Sub-group analysis was carried out in patients naive to prior disease-modifying therapy or those who previously received interferon (IFN) or glatiramer acetate (GA).

Participants treated with IFN/GAs demonstrated significant improvements in radiological and clinical endpoints over one year with diroximel fumarate, compared to baseline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biogen said that adjusted annualised relapse rate decreased by 72% between baseline and week 48 when treated with the study drug.

Around 30.9% of patients discontinued the diroximel fumarate group within one year of treatment due to gastrointestinal (GI) adverse events. These events were observed to be generally mild or moderate in severity and typically occurred within the first month of therapy.

Biogen research and development (R&D) executive vice-president Michael Ehlers said: “We are excited about these data for diroximel fumarate and believe this distinct oral fumarate has the potential to be a meaningful treatment option for people living with MS.”

The drug is being evaluated by Alkermes in the five-week, head-to-head EVOLVE-MS-2 study in patients with relapsing-remitting MS, compared to dimethyl fumarate.